Aerobiotix collaborates with Cardinal Health to get Clean Air Technology into more Hospitals and Surgical Centers | Aerobiotix

Aerobiotix collaborates with Cardinal Health to get Clean Air Technology into more Hospitals and Surgical Centers

Sep 27, 2021 | News, News and Events


Units Proven to Remove Airborne Microorganisms, Including Coronavirus

For Immediate Release

Download PDF

[MIAMISBURG, OHIO] — U.S.-based Aerobiotix, an innovative clinical manufacturing company, is on a mission to improve the air quality in operating rooms. Thanks to a new distribution agreement with Cardinal Health, its technology will soon be available in more hospitals and surgical centers to help reduce the risk of infection and contamination of infectious aerosols including SARS-COV-2.

Cardinal Health recently added Aerobiotix as a preferred supplier in their Performance Plus™ program. This program offers hospitals efficiency and value when selecting products, and Aerobiotix is the preferred supplier in the air quality product category.

“Having an innovative product in our portfolio that is proven to improve the air quality in operating rooms and surgical centers is important to us,” said Marc DeLorenzo, SVP Strategic Sourcing for Cardinal Health. “Collaborating with Aerobiotix allows us to provide a product that can benefit both the healthcare worker and their patients.”

Cardinal Health serves nearly 90% of U.S. hospitals, positioning Aerobiotix’s clinically-proven non-turbulent ultraclean air system, Illuvia®, to have an immediate impact by reducing the risk of contamination and infection in operating rooms. Illuvia® is the only technology in this space that has been approved by the U.S. Food and Drug Administration (FDA) to eliminate airborne viruses.

Benefits of Illuvia®:
● Eliminates airborne microorganisms, including SARS-COV-2
● Improves air quality for frontline healthcare workers
● Reduces surgical infection rates by as much as 50%
● Combines the gold standard of HEPA filtration with ultraviolet air recirculation

Aerobiotix technology is currently being used by over 100 facilities worldwide and will continue improving patient and staff safety as a result of this new collaboration with Cardinal Health. This will be one of the first products offered in this program with plans to release additional technology impacting other healthcare environments.

“We are thrilled to announce our marketing and distribution relationship with Cardinal Health providing transformational air quality technology to meet rapidly growing environmental needs in healthcare,” said David Kirschman, MD, Aerobiotix founder and CEO. “This relationship will significantly expand our sales and marketing reach and will drive further penetration of Aerobiotix products, including the intraoperative Illuvia® system. The mutual commitment of our organizations to improve patient and staff safety, reduce hospital-acquired infections and curtail unnecessary costs underscores the synergies of this partnership.”


About Aerobiotix
Aerobiotix is a pioneer in air quality management solutions for healthcare, assisted living, and education. Its medical-grade products use ultraviolet light, HEPA filters, and proprietary filtration to remove 99.9% of bacteria, viruses, VOCs, and more. This proven technology is quiet, safe, and designed to run continuously in occupied rooms to reduce risk of infections and to improve environmental safety. Equipped with integrated tracking, Aerobiotix solutions help facilities worldwide measure and proactively manage air quality. Learn more at

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is Essential to care™ *. Information about Cardinal Health is available at

*Performance Plus™ and Essential to care™ are Cardinal Health owned trademarks and may be registered in the US and in other countries.

Contact Information
Kristin Porco | 616.717.3511

Download PDF



Sr. Vice President of Global Sales and Marketing

Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.



Vice President of Global Marketing

Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.



President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D. Director Scientific Affairs


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE Chief Commercial Officer


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D. VP of Clinical and Medical Affairs


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO Vice President of Engineering


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ Vice President of Client Services


Vice President of Strategic Accounts

Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.

MICHAEL SCHMITZ Chief Financial Officer


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.